Sarepta Therapeutics, Inc. (BVMF:S1RP34)

Brazil flag Brazil · Delayed Price · Currency is BRL
4.680
-0.150 (-3.11%)
At close: Feb 9, 2026
Market Cap9.96B -84.8%
Revenue (ttm)12.86B +47.1%
Net Income-1.45B
EPS-14.77
Shares Outn/a
PE Ration/a
Forward PE10.25
Dividendn/a
Ex-Dividend Daten/a
Volume2,400
Average Volume3,378
Open4.660
Previous Close4.830
Day's Range4.650 - 4.730
52-Week Range2.880 - 35.250
Beta0.39
RSI35.31
Earnings DateFeb 25, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1980
Employees 1,372
Stock Exchange Brazil Stock Exchange
Ticker Symbol S1RP34
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements